In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Richardson introduces the study, which examined the use of lenalidomide, bortezomib and dexamethasone (RVd) in tandem with stem cell transplantation and lenalidomide continuous maintenance in patients newly diagnosed with multiple myeloma under the age of 65, and provides context for its significance in the treatment of multiple myeloma.
“The results, we
